Late hyperenhancement in gadolinium-enhanced magnetic resonance imaging: comparison of hypertrophic cardiomyopathy patients with and without nonsustained ventricular tachycardia

被引:28
作者
Dimitrow, Pawel Petkow
Klimeczek, Piotr
Vliegenthart, Rozemarijn
Pasowicz, Mieczyslaw
Oudkerk, Matthijs
Podolec, Piotr
Tracz, Wieslawa
Dubiel, Jacek S.
机构
[1] Jagiellonian Univ, Coll Med, Dept Cardiol 2, PL-31501 Krakow, Poland
[2] John Paul Hosp 2, Ctr Diag & Rehabil Heart & Lung Dis, Krakow, Poland
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, Groningen, Netherlands
[4] Jagiellonian Univ, Coll Med, Dept Cardiac & Vasc Dis, Krakow, Poland
关键词
hypertrophic cardiomyopathy; magnetic resonance imaging;
D O I
10.1007/s10554-007-9209-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim To assess the extent of hyperenhancement in hypertrophic cardiomyopathy (HCM) patients with nonsustained ventricular tachycardia (NSVT) in comparison to patients without NSVT. Design In HCM patients, NSVT in Holter monitoring is a risk factor for sudden cardiac death; however, its positive predictive value is low. Varying risk of sudden death related to NSVT may be dependent on the heterogeneous extent of the arrhythmogenic substrate, which seems to be visible as hyperenhancement in gadolinium-enhanced magnetic resonance imaging (MRI). Methods Hyperenhancement was assessed in 47 HCM patients (30 males and 17 females, mean age 42 +/- 12 years): 32 patients had NSVT, 15 patients had no NSVT. The extent of hyperenhancement was calculated by software and expressed as a mass. Results In HCM patients with NSVT 97% had some extent of hyperenhancement on MRI, ranging from 1 to 76 g. The mean mass of hyperenhanced myocardium was 19 +/- 18 g (8.1 +/- 7.6% of total left ventricular mass). In HCM patients without NSVT, a significantly lower percentage of patients (60%) had hyperenhancement (P < 0.05). However, the amount of hyperenhanced myocardium was not significantly different (13 +/- 19 g, 6.3 +/- 9.1% of total left ventricular mass; P < 0.05). Conclusions Hyperenhancement was visible in almost all HCM patients with NSVT (97%) and in a significantly lower percentage of patients without NSVT (60%). Whether this finding explains the increased risk of sudden death in case of NSVT is not clear, since the extent of hyperenhancement was not significantly different between the two groups.
引用
收藏
页码:77 / 83
页数:7
相关论文
共 20 条
[1]   Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population [J].
Cecchi, F ;
Olivotto, I ;
Montereggi, A ;
Squillatini, G ;
Dolara, A ;
Maron, BJ .
HEART, 1998, 79 (04) :331-336
[2]   Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy [J].
Choudhury, L ;
Mahrholdt, H ;
Wagner, A ;
Choi, KM ;
Elliott, MD ;
Klocke, FJ ;
Bonow, RO ;
Judd, RM ;
Kim, RJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (12) :2156-2164
[3]   Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients [J].
Elliott, PM ;
Poloniecki, J ;
Dickie, S ;
Sharma, S ;
Monserrat, L ;
Varnava, A ;
Mahon, NG ;
McKenna, WJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) :2212-2218
[4]   Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy - In vivo imaging of the pathologic substrate for premature cardiac death? [J].
Kim, RJ ;
Judd, RM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (09) :1568-1572
[5]   Hypertrophic cardiomyopathy in a large community-based population: Clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration [J].
Kofflard, MJM ;
Ten Cate, FJ ;
van der Lee, C ;
van Domburg, RT .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) :987-993
[6]   PROGNOSTIC-SIGNIFICANCE OF 24-HOUR AMBULATORY ELECTROCARDIOGRAPHIC MONITORING IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY - A PROSPECTIVE-STUDY [J].
MARON, BJ ;
SAVAGE, DD ;
WOLFSON, JK ;
EPSTEIN, SE .
AMERICAN JOURNAL OF CARDIOLOGY, 1981, 48 (02) :252-257
[7]   HYPERTROPHIC CARDIOMYOPATHY - DISCUSSION OF NOMENCLATURE [J].
MARON, BJ ;
EPSTEIN, SE .
AMERICAN JOURNAL OF CARDIOLOGY, 1979, 43 (06) :1242-1244
[8]  
MCKENNA WJ, 1981, BRIT HEART J, V46, P168
[9]   Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death [J].
McKenna, WJ ;
Behr, ER .
HEART, 2002, 87 (02) :169-176
[10]   THE PROGNOSTIC-SIGNIFICANCE OF NONSUSTAINED VENTRICULAR-TACHYCARDIA IN HYPERTROPHIC CARDIOMYOPATHY [J].
MCKENNA, WJ ;
SADOUL, N ;
SLADE, AKB ;
SAUMAREZ, RC .
CIRCULATION, 1994, 90 (06) :3115-3117